↓ Skip to main content

Indacaterol, a once-daily beta2 -agonist, versus twice-daily beta2 -agonists or placebo for chronic obstructive pulmonary disease

Overview of attention for article published in Cochrane database of systematic reviews, January 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
1 news outlet
twitter
32 tweeters
facebook
4 Facebook pages
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
156 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Indacaterol, a once-daily beta2 -agonist, versus twice-daily beta2 -agonists or placebo for chronic obstructive pulmonary disease
Published in
Cochrane database of systematic reviews, January 2015
DOI 10.1002/14651858.cd010139.pub2
Pubmed ID
Authors

James B Geake, Eli J Dabscheck, Richard Wood-Baker, Christopher J Cates

Twitter Demographics

The data shown below were collected from the profiles of 32 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
United States 1 <1%
Sweden 1 <1%
Unknown 152 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 17%
Student > Master 25 16%
Student > Ph. D. Student 18 12%
Student > Bachelor 17 11%
Student > Doctoral Student 12 8%
Other 30 19%
Unknown 27 17%
Readers by discipline Count As %
Medicine and Dentistry 72 46%
Nursing and Health Professions 20 13%
Pharmacology, Toxicology and Pharmaceutical Science 9 6%
Social Sciences 5 3%
Psychology 4 3%
Other 18 12%
Unknown 28 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2018.
All research outputs
#712,217
of 16,521,405 outputs
Outputs from Cochrane database of systematic reviews
#1,882
of 11,524 outputs
Outputs of similar age
#14,028
of 309,385 outputs
Outputs of similar age from Cochrane database of systematic reviews
#48
of 245 outputs
Altmetric has tracked 16,521,405 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,524 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.3. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,385 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 245 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.